Standardized Definitions of Bleeding After Transbronchial Lung Biopsy: A Delphi Consensus Statement From the Nashville Working Group.
biopsy (lung)
bleeding
bronchoscopy
interventional bronchoscopy
Journal
Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
22
09
2019
revised:
03
12
2019
accepted:
25
01
2020
pubmed:
19
2
2020
medline:
22
5
2021
entrez:
19
2
2020
Statut:
ppublish
Résumé
Transbronchial lung biopsies are commonly performed for a variety of indications. Although generally well tolerated, complications such as bleeding do occur. Description of bleeding severity is crucial both clinically and in research trials; to date, there is no validated scale that is widely accepted for this purpose. Can a simple, reproducible tool for categorizing the severity of bleeding after transbronchial biopsy be created? Using the modified Delphi method, an international group of bronchoscopists sought to create a new scale tailored to assess bleeding severity among patients undergoing flexible bronchoscopy with transbronchial lung biopsies. Cessation criteria were specified a priori and included reaching > 80% consensus among the experts or three rounds, whichever occurred first. Thirty-six expert bronchoscopists from eight countries, both in academic and community practice settings, participated in the creation of the scale. After the live meeting, two iterations were made. The second and final scale was vetted by all 36 participants, with a weighted average of 4.47/5; 53% were satisfied, and 47% were very satisfied. The panel reached a consensus and proposes the Nashville Bleeding Scale. The use of a simplified airway bleeding scale that can be applied at bedside is an important, necessary tool for categorizing the severity of bleeding. Uniformity in reporting clinically significant airway bleeding during bronchoscopic procedures will improve the quality of the information derived and could lead to standardization of management. In addition to transbronchial biopsies, this scale could also be applied to other bronchoscopic procedures, such as endobronchial biopsy or endobronchial ultrasound-guided needle aspiration.
Sections du résumé
BACKGROUND
Transbronchial lung biopsies are commonly performed for a variety of indications. Although generally well tolerated, complications such as bleeding do occur. Description of bleeding severity is crucial both clinically and in research trials; to date, there is no validated scale that is widely accepted for this purpose. Can a simple, reproducible tool for categorizing the severity of bleeding after transbronchial biopsy be created?
METHODS
Using the modified Delphi method, an international group of bronchoscopists sought to create a new scale tailored to assess bleeding severity among patients undergoing flexible bronchoscopy with transbronchial lung biopsies. Cessation criteria were specified a priori and included reaching > 80% consensus among the experts or three rounds, whichever occurred first.
RESULTS
Thirty-six expert bronchoscopists from eight countries, both in academic and community practice settings, participated in the creation of the scale. After the live meeting, two iterations were made. The second and final scale was vetted by all 36 participants, with a weighted average of 4.47/5; 53% were satisfied, and 47% were very satisfied. The panel reached a consensus and proposes the Nashville Bleeding Scale.
CONCLUSIONS
The use of a simplified airway bleeding scale that can be applied at bedside is an important, necessary tool for categorizing the severity of bleeding. Uniformity in reporting clinically significant airway bleeding during bronchoscopic procedures will improve the quality of the information derived and could lead to standardization of management. In addition to transbronchial biopsies, this scale could also be applied to other bronchoscopic procedures, such as endobronchial biopsy or endobronchial ultrasound-guided needle aspiration.
Identifiants
pubmed: 32067944
pii: S0012-3692(20)30272-5
doi: 10.1016/j.chest.2020.01.036
pmc: PMC7403751
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
393-400Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM125498
Pays : United States
Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Références
Monaldi Arch Chest Dis. 2009 Mar;71(1):8-14
pubmed: 19522159
Am J Med Sci. 1987 Nov;294(5):301-9
pubmed: 3425580
Semin Arthritis Rheum. 2011 Oct;41(2):95-105
pubmed: 21420149
Chest. 1995 Feb;107(2):430-2
pubmed: 7842773
J Thorac Oncol. 2019 Mar;14(3):445-458
pubmed: 30476574
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
Chest. 1997 Aug;112(2):440-4
pubmed: 9266882
Respiration. 2012;84(4):312-8
pubmed: 22889938
Thorax. 2013 Aug;68 Suppl 1:i1-i44
pubmed: 23860341
Respiration. 2018;95(3):188-200
pubmed: 29316560
Eur Respir J. 2008 Oct;32(4):1131-2
pubmed: 18827169
Chest. 2006 Mar;129(3):734-7
pubmed: 16537875
J Clin Epidemiol. 2014 Apr;67(4):401-9
pubmed: 24581294